Endophthalmitis after Minimally Invasive Glaucoma Surgery

Ophthalmology. 2021 Dec;128(12):1777-1779. doi: 10.1016/j.ophtha.2021.06.004. Epub 2021 Jun 5.

Authors

Matthew R Starr¹, Denis Huang¹, Rachel N Israilevich¹, Michael J Ammar¹, Luv G Patel¹, Omesh P Gupta¹, Mitchell S Fineman¹, Jason Hsu¹, Richard S Kaiser¹, Ajay E Kuriyan¹, Sonia Mehta¹, Carl H Park¹, Marc J Spirn¹, Samuel D Martin², Ayan Chatterjee³, Daniel Lee³, Michael J Pro³, Marlene R Moster³, Sunir J Garg¹, Yoshihiro Yonekawa⁴

Affiliations

¹ Mid Atlantic Retina, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
² Johns Hopkins University, Baltimore, Maryland; Glaucoma Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
³ Glaucoma Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
⁴ Mid Atlantic Retina, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania. Electronic address: yyonekawa@midatlanticretina.com.

PMID: 34102231
DOI: 10.1016/j.ophtha.2021.06.004

No abstract available

Keywords: Endophthalmitis; Glaucoma; Minimally invasive glaucoma surgery; Retina.

MeSH terms

Aged
Aged, 80 and over
Anti-Bacterial Agents / therapeutic use
Endophthalmitis / diagnosis
Endophthalmitis / drug therapy
Endophthalmitis / microbiology*
Eye Infections, Bacterial / diagnosis
Eye Infections, Bacterial / drug therapy
Eye Infections, Bacterial / microbiology*
Female
Glaucoma Drainage Implants / adverse effects*
Glaucoma, Open-Angle / surgery*
Humans
Male
Middle Aged
Minimally Invasive Surgical Procedures / adverse effects*
Postoperative Complications*
Retrospective Studies
Staphylococcal Infections / diagnosis
Staphylococcal Infections / drug therapy
Staphylococcal Infections / microbiology*

Substances

Anti-Bacterial Agents